<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="93897">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01659255</url>
  </required_header>
  <id_info>
    <org_study_id>ONO-4059POE001</org_study_id>
    <nct_id>NCT01659255</nct_id>
  </id_info>
  <brief_title>Phase I Study of ONO-4059 Given as Monotherapy in Patients With Relapsed/Refractory NHL and CLL</brief_title>
  <official_title>Phase I Dose-escalation Study to Investigate the Safety and Tolerability of ONO-4059 Given as Monotherapy in Patients With Relapsed/Refractory Non-Hodgkin's Lymphoma and/or Chronic Lymphocytic Leukaemia.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ono Pharmaceutical Co. Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ono Pharmaceutical Co. Ltd</source>
  <oversight_info>
    <authority>United Kingdom: Medicines and Healthcare Products Regulatory Agency</authority>
    <authority>France: Agence Nationale de Sécurité du Médicament et des produits de santé</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open-label, multi-centre, phase I dose-escalation study to investigate the safety
      and tolerability of ONO-4059 given as monotherapy to patients with relapsed/refractory NHL
      and CLL. ONO-4059 will be administered orally, once daily(QD)as a flat dose, for up to
      maximum 24 cycles of treatment.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      An open-label, multi-centre, non-randomised phase I dose-escalation study to investigate the
      safety and tolerability of ONO-4059 given as monotherapy in patients with
      relapsed/refractory Non-Hodgkin's lymphoma (NHL) and relapsed/refractory chronic lymphocytic
      leukaemia (CLL). Non-Hodgkin's lymphoma are a heterogeneous group of malignancies which have
      a varied clinical and biological features. Leukaemia is a type of cancer of the blood or
      bone marrow characterized by an abnormal increase of immature white blood cells. Chronic
      lymphocytic leukaemia (CLL) is the most common type of adult leukaemia affecting the blood
      and bone marrow.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>August 2012</start_date>
  <completion_date type="Anticipated">October 2016</completion_date>
  <primary_completion_date type="Anticipated">April 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>1. Safety and tolerability and the incidence of dose limiting toxicities (DLTs). DLTs will be assessed within the first 28 days from receiving the first dose of ONO-4059.</measure>
    <time_frame>6 - 24 months</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Frequency, severity and relatedness of AEs.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>1. Pharmacokinetic/pharmacodynamic assessments</measure>
    <time_frame>During 1 cycle = 28 days</time_frame>
    <safety_issue>No</safety_issue>
    <description>Pharmacodynamics of ONO-4059 (ie, drug occupancy of Btk and effect on biological markers of B cell function.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>2. Tumour response</measure>
    <time_frame>Cycles 3 and 6, 9, 12, 18, 24 (28 days for each cycle).</time_frame>
    <safety_issue>No</safety_issue>
    <description>Overall response rate as defined by guidelines on NHL and CLL, duration of response, CR rate, PFS, OS</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">72</enrollment>
  <condition>Non Hodgkins Lymphoma</condition>
  <condition>Chronic Lymphocytic Leukaemia</condition>
  <arm_group>
    <arm_group_label>Experimental</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ONO-4059</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ONO-4059</intervention_name>
    <description>ONO-4059 QD up to maximum 24 cycles (1 cycle = 28 days). Start dose is 20mg.</description>
    <arm_group_label>Experimental</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Males or females with a confirmed diagnosis of and documented history of relapsed or
             refractory malignant disease (B-cell lymphoma and/or CLL) for which no therapy of
             curative or high priority exists and for whom treatment with a Btk inhibitor may be
             deemed appropriate.

          2. Age ≥18 years.

          3. Eastern Cooperative Oncology Group (ECOG) performance status of ≤2.

        Exclusion Criteria:

          1. Central nervous system (CNS) lymphoma.

          2. Women who are pregnant or lactating.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Department</last_name>
    <role>Study Director</role>
    <affiliation>Ono Pharmaceutical Co. Ltd</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ono Pharma UK Ltd</last_name>
  </overall_contact>
  <location>
    <facility>
      <name>CHRU - Hopital Claude HURIEZ</name>
      <address>
        <city>Lille</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Morschhauser</last_name>
      <phone>+33 3 20444290</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre hospitalier Lyon Sud</name>
      <address>
        <city>Lyon</city>
        <zip>69495</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Salles</last_name>
      <phone>+33 4 7886 4307</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU St Eloi</name>
      <address>
        <city>Montpellier</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cartron</last_name>
      <phone>+33-4-67338079</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital of Wales</name>
      <address>
        <city>Cardiff</city>
        <zip>CF14 4XW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fegan</last_name>
      <phone>+44 (0)2920 745654</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Leicester Royal Infirmary</name>
      <address>
        <city>Leicester</city>
        <zip>LE1 5WW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dyer</last_name>
      <phone>+44-(0)116-252-5589</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Derriford Hospital</name>
      <address>
        <city>Plymouth</city>
        <zip>PL6 8DH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rule</last_name>
      <phone>+44 (0)1752 517505</phone>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>June 2013</verification_date>
  <lastchanged_date>October 22, 2013</lastchanged_date>
  <firstreceived_date>July 6, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Lymphocytic, Chronic, B-Cell</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
